Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BTG plc
Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.
Acquisition activity in the biopharmaceutical sector saw a strong uptick in deal value and an exponential increase in total deal value during the fourth quarter, according to data from Evaluate.
Japan adds a batch of new drugs, including Wegovy, to the national health insurance reimbursement tariff, but discussions over Leqembi for Alzheimer’s are still ongoing, with indications that repricing could be possible if demand expands quickly.
Just over six months after getting a complete response letter for its prodrug carbidopa and levodopa combination product, the US major has acquired Mitokinin and its selective PINK1 activator which could potentially be a disease-modifying treatment for Parkinson’s disease.
- Specialty Pharmaceuticals
- Infusion Therapy Equipment and Supplies
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Biocompatibles International plc
- Ekos Corporation
- Galil Medical, Inc.
- Novate Medical Ltd.
- PneumRx Inc.
- Protherics PLC
- Roxwood Medical
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.